There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenaya Therapeutics (TNYA – Research Report) and Gain Therapeutics (GANX – Research Report) with bullish sentiments.
Gain Therapeutics (GANX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Thursday at $3.19, close to its 52-week low of $2.80.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.00, which is a 217.5% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNYA:
- Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
- Tenaya Therapeutics publishes preclinical data on heart disease in Circulation
- Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
- Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
- Tenaya Therapeutics price target lowered to $17 from $18 at Canaccord
